On Mar. 11, 2021, ContraFect announced that it had been awarded a cost-share contract from the Biomedical Advanced Research and Development Authority (BARDA). The Company was to receive $9.8 million in initial funding and up to an additional $77.0 million.

The initial funding supported ContraFectﾒs pivotal Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) superiority study of exebacase in patients with Staph aureus bacteremia, including right-sided endocarditis.